STOCK TITAN
  1. Home
  2. News
  3. GNPX

Genprex Inc - GNPX STOCK NEWS

Welcome to our dedicated news page for Genprex (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genprex's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genprex's position in the market.

News
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
Rhea-AI Summary
Genprex, Inc. announced a 1-for-40 reverse stock split of its common stock, effective February 2, 2024, to increase the market price per share and regain compliance with Nasdaq listing requirements. The reverse split will not change the par value or modify the rights of the common stock, and will result in approximately 1.5 million shares of common stock issued and outstanding. The reverse stock split will affect all stockholders uniformly, and the company's transfer agent will maintain the book-entry records for the common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.09%
Tags
stock split
-
News
Genprex Provides Business Update and Outlook for 2024
Rhea-AI Summary
Genprex, Inc. (GNPX) previews plans for advancing its diabetes and oncology gene therapy programs in 2024, including the opening of Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies for enrollment in January 2024. The company is poised for FDA guidance regarding its diabetes gene therapy program in 2024. Genprex achieved significant milestones in 2023, including Fast Track Designations for REQORSA Immunogene Therapy and process improvements in manufacturing operations. The company's focus on developing life-changing therapies for patients with cancer and diabetes positions it for a strong 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
none
-
News
Genprex to Present at BIO-Europe 2023 Conference
Rhea-AI Summary
Genprex, Inc. announced that its Executive Vice President, Catherine Vaczy, will provide an overview of the company's gene therapies for cancer and diabetes at the BIO-Europe 2023 Conference in Munich, Germany. The presentation will take place on November 7, 2023, at 4:45 p.m. UTC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
conferences
News
Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"
Rhea-AI Summary
Genprex to host virtual key opinion leader event on current state of lung cancer treatments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
conferences
-
News
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Rhea-AI Summary
Genprex announces positive clinical and preclinical data for REQORSA® in the treatment of lung cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
conferences
-
News
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
Rhea-AI Summary
Genprex Inc. (GNPX) granted FDA orphan drug designation for REQORSA immunogene therapy in development for small cell lung cancer (SCLC)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
clinical trial
News
Genprex to Present at Upcoming September Investor Conference
Rhea-AI Summary
Genprex, Inc. will present an overview of its gene therapies for cancer and diabetes at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be given by Ryan Confer, the company's Chief Financial Officer, on September 13, 2023, at 3:00 p.m. ET. The presentation will be available for replay on Genprex's website. Investors can also schedule one-on-one meetings with Genprex management through the conference portals or by contacting Investor Relations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
conferences
-
News
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs
Rhea-AI Summary
Genprex strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes. Dr. Suzanne Thornton-Jones appointed as Senior VP, Regulatory Affairs. She brings over 25 years of experience in drug development and regulatory strategy. The company has granted her 200,000 options at an exercise price of $0.44. Options vest in equal one-third installments over the next three years and are exercisable for a period of ten years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.02%
Tags
management
-
News
Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer
Rhea-AI Summary
Genprex receives FDA Orphan Drug Designation for REQORSA Immunogene Therapy in the treatment of small cell lung cancer (SCLC). FDA also grants Fast Track Designation for REQORSA in combination with other drugs for various indications. Acclaim-3 clinical trial expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
clinical trial
News
Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Genprex, Inc. has announced the closing of its registered direct offering, raising approximately $7.5 million. The offering consisted of 7,425,744 shares of common stock and warrants to purchase up to 7,425,744 shares of common stock at a price of $1.01 per share. The net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
Stock GNPX logo
Genprex Inc

Nasdaq:GNPX

GNPX Rankings

N/A Ranked by Market Cap
#5401 Ranked by Stock Gains
N/A Ranked by Dividends

GNPX Stock Data

5.12M
1.88M
0.85%
6.59%
3.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Austin

About GNPX

genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur